Press coverage about Alder BioPharmaceuticals (NASDAQ:ALDR) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alder BioPharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.2832583502885 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Closed Significantly Above Its 50 Day Average – First News 24 (firstnewspaper24.com)
- Technical Indicators should not be overlooked on Alder Biopharmaceuticals, Inc. (ALDR) – Wall Street Morning (wallstreetmorning.com)
- Analysts said to Buy Healthcare Stock: Alder Biopharmaceuticals, Inc. (ALDR) – Street Observer (press release) (streetobserver.com)
- Alder Biopharmaceuticals, Inc. (ALDR) registers a price change of -2.35% while Wright Medical Group NV (WMGI … – Stocks Gallery (stocksgallery.com)
- RSI 81.80 Signals Alder Biopharmaceuticals, Inc. (ALDR) stock could lead to a downward move – Voice Of Analysts (analystsbuzz.com)
Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) opened at 12.35 on Thursday. The firm’s 50-day moving average is $10.74 and its 200-day moving average is $14.58. The company’s market cap is $836.26 million. Alder BioPharmaceuticals has a 12 month low of $8.60 and a 12 month high of $34.30.
Several brokerages recently weighed in on ALDR. BidaskClub raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Credit Suisse Group set a $11.00 price objective on shares of Alder BioPharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, August 24th. Cowen and Company began coverage on shares of Alder BioPharmaceuticals in a research note on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $26.00 price objective (down previously from $36.00) on shares of Alder BioPharmaceuticals in a research note on Thursday, August 10th. Finally, Royal Bank Of Canada began coverage on shares of Alder BioPharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $17.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $28.69.
TRADEMARK VIOLATION WARNING: “Alder BioPharmaceuticals (ALDR) Given Daily News Sentiment Score of 0.21” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/12/alder-biopharmaceuticals-aldr-given-daily-news-sentiment-score-of-0-21.html.
In related news, Director Stephen M. Dow bought 25,000 shares of the business’s stock in a transaction dated Tuesday, July 18th. The shares were purchased at an average price of $10.00 per share, with a total value of $250,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 10.60% of the company’s stock.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
What are top analysts saying about Alder BioPharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alder BioPharmaceuticals Inc. and related companies.